Today's patients commonly take two or more prescription drugs concurrently, a fact that greatly increases the possibility for drug-drug interactions (DDIs) to occur. Posing risk to patients and developers alike, the potential for DDIs can’t be ignored.

A well-recognized cause for DDIs is inhibition of CYP enzymes. In this webinar, our scientists discuss the current methodologies used to study metabolism-dependent inhibition and present a strategy for risk evaluation of CYP-mediated DDIs.


  • Jelle Reinen, PhD, MSc, Study Director, Charles River
  • Stuart Robjohns, BSc, Senior Scientist, DMPK, Charles River